NCT01705236 - A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2012

Primary Completion Date

February 18, 2019

Study Completion Date

February 18, 2019

Conditions

Relapsing Remitting Multiple Sclerosis RRMS

Interventions

DRUG

Fingolimod

All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.

Trial Locations (10)

8091

Novartis Investigative Site, Zurich

18057

Novartis Investigative Site, Rostock

30625

Novartis Investigative Site, Hanover

40225

Novartis Investigative Site, Düsseldorf

44791

Novartis Investigative Site, Bochum

53105

Novartis Investigative Site, Bonn

69120

Novartis Investigative Site, Heidelberg

89081

Novartis Investigative Site, Ulm

01307

Novartis Investigative Site, Dresden

04103

Novartis Investigative Site, Leipzig